Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Review Article

Mast Cell's Role in Cytokine Release Syndrome and Related Manifestations of COVID-19 Disease

Author(s): Öner Özdemir*, Azize Yasemin Göksu Erol and Ümmügülsüm Dikici

Volume 28, Issue 40, 2022

Published on: 03 November, 2022

Page: [3261 - 3268] Pages: 8

DOI: 10.2174/1381612829666221027114123

Price: $65

Abstract

In this narrative review, firstly, we describe the characteristics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the pathogenesis of its infection in humans. Later, the importance of mast cells in SARS-CoV-2 infection and their role in Coronavirus Disease 2019 (COVID-19) will be discussed. SARS-CoV-2 is a transmissible agent frequently detected in some mammalian species and also in humans. Literature data published in PubMed that covered mast cells' role in cytokine release syndrome and related manifestations of COVID-19 disease were reviewed by the authors independently and collectively. Recommendations for the management of cytokine release syndrome and related manifestations were made by the authors. Mast cells are concentrated in environments where they encounter viruses, bacteria, and toxins, especially in the skin, nasal mucosa, lungs, airways, gastrointestinal tract, and meninges, to prevent their entry into the human body. Once SARS-CoV-2 enters the host, it stimulates one of the mast cells, together with pre-existing innate immune cells that form a defensive barrier in the submucosa of the respiratory tract and nasal cavities against pathogenic microorganisms. The roles of mast cells in SARS-CoV-2-induced hyperinflammation and cytokine storms have recently been one of the hot topics in the literature. Physicians should keep in mind the mast cells' role in cytokine release syndrome and related manifestations of COVID-19 disease. Mast cell-targeting therapies (e.g., H1 and H2 receptor antagonists) can reduce the severity and course of the disease when used after complications associated with COVID-19 are suspected or seen.

[1]
Özdemir Ö. Coronavirus Disease 2019 (COVID-19): Diagnosis and management (narrative review). Erciyes Med J 2020; 42(3): 242-7.
[http://dx.doi.org/10.14744/etd.2020.99836]
[2]
Kempuraj D, Selvakumar GP, Ahmed ME, et al. COVID-19, mast cells, cytokine storm, psychological stress, and neuroinflammation. Neuroscientist 2020; 26(5-6): 402-14.
[http://dx.doi.org/10.1177/1073858420941476] [PMID: 32684080]
[3]
Özdemir Ö, Erkun O. Solving puzzle of the immunopatho-genesis for management of COVID-19 disease. MOJ Immunol 2020; 7(1): 13-5.
[4]
Bourgonje AR, Abdulle AE, Timens W, et al. Angiotensin‐converting enzyme 2 (ACE2), SARS‐CoV ‐2 and the pathophysiology of coronavirus disease 2019 (COVID ‐19). J Pathol 2020; 251(3): 228-48.
[http://dx.doi.org/10.1002/path.5471] [PMID: 32418199]
[5]
Lam HY, Tergaonkar V, Kumar AP, Ahn KS. Mast cells: Therapeutic targets for COVID ‐19 and beyond. IUBMB Life 2021; 73(11): 1278-92.
[http://dx.doi.org/10.1002/iub.2552] [PMID: 34467628]
[6]
Stelekati E, Bahri R, D’Orlando O, et al. Mast cell-mediated antigen presentation regulates CD8+ T cell effector functions. Immunity 2009; 31(4): 665-76.
[http://dx.doi.org/10.1016/j.immuni.2009.08.022] [PMID: 19818652]
[7]
Özdemir Ö. Immunosurveillance function of human mast cell? World J Gastroenterol 2005; 11(44): 7054-6.
[http://dx.doi.org/10.3748/wjg.v11.i44.7054] [PMID: 16437618]
[8]
Özdemir O, Savaşan S. The role of mast cells in bone marrow diseases. J Clin Pathol 2004; 57(1): 108-a-9.
[http://dx.doi.org/10.1136/jcp.57.1.108-a] [PMID: 14693852]
[9]
Özdemir O. Mast cells and the tumor-associated neoangio-genesis. Med Sci Monit 2006; 12(6): LE9-LE11.
[PMID: 16733492]
[10]
St John AL. Influence of mast cells on dengue protective immunity and immune pathology. PLoS Pathog 2013; 9(12): e1003783.
[http://dx.doi.org/10.1371/journal.ppat.1003783] [PMID: 24367254]
[11]
Yılmaz EA, Özdemir Ö. Reflection from pathophysiology and role of immune system onto clinic table and management in SARS-CoV-2 infection. Sakarya Med J 2022; 12(1): 178-87.
[12]
Kritas SK, Ronconi G, Caraffa A, Gallenga CE, Ross R, Conti P. Mast cells contribute to coronavirus-induced inflammation: new anti-inflammatory strategy. J Biol Regul Homeost Agents 2020; 34(1): 9-14.
[PMID: 32013309]
[13]
Tissera H, Rathore APS, Leong WY, et al. Chymase level is a predictive biomarker of dengue hemorrhagic fever in pediatric and adult patients. J Infect Dis 2017; 216(9): 1112-21.
[http://dx.doi.org/10.1093/infdis/jix447] [PMID: 28968807]
[14]
St John AL, Rathore APS, Yap H, et al. Immune surveillance by mast cells during dengue infection promotes natural killer (NK) and NKT-cell recruitment and viral clearance. Proc Natl Acad Sci USA 2011; 108(22): 9190-5.
[http://dx.doi.org/10.1073/pnas.1105079108] [PMID: 21576486]
[15]
Hafezi B, Chan L, Knapp JP, et al. Cytokine storm syndrome in SARS-CoV-2 infections: A functional role of mast cells. Cells 2021; 10(7): 1761.
[http://dx.doi.org/10.3390/cells10071761] [PMID: 34359931]
[16]
Murdaca G, Di Gioacchino M, Greco M, et al. Basophils and mast cells in COVID-19 pathogenesis. Cells 2021; 10(10): 2754.
[http://dx.doi.org/10.3390/cells10102754] [PMID: 34685733]
[17]
Conti P, Caraffa A, Tetè G, et al. Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19. J Biol Regul Homeost Agents 2020; 34(5): 1629-32.
[PMID: 32945158]
[18]
Zhou Z, Ren L, Zhang L, et al. Heightened innate immune responses in the respiratory tract of COVID‐19 patients. Cell Host Microbe 2020; 27(6): 883-890.e2.
[http://dx.doi.org/10.1016/j.chom.2020.04.017] [PMID: 32407669]
[19]
Soria-Castro R, Meneses-Preza YG, Rodríguez-López GM, et al. Severe COVID‐19 is marked by dysregulated serum levels of carboxypeptidase A3 and serotonin. J Leukoc Biol 2021; 110(3): 425-31.
[http://dx.doi.org/10.1002/JLB.4HI0221-087R] [PMID: 34057753]
[20]
Gebremeskel S, Schanin J, Coyle KM, et al. Mast cell and eosinophil activation are associated with COVID-19 and TLR- mediated viral inflammation: implications for an anti-siglec-8 antibody. Front Immunol 2021; 12: 650331.
[http://dx.doi.org/10.3389/fimmu.2021.650331] [PMID: 33777047]
[21]
Tan J, Anderson DE, Rathore AP, et al. Signatures of mast cell activation are associated with severe COVID-19. medRxiv 2021; 2021.05.31.21255594.
[http://dx.doi.org/10.1101/2021.05.31.21255594]
[22]
Özdemir Ö, Dikici Ü. Incidence of SARS-CoV-2 infection in asthma patients on omalizumab therapy. Erciyes Med J 2022; 44(5)
[http://dx.doi.org/10.14744/etd.2022.28938]
[23]
Schön MP, Berking C, Biedermann T, et al. COVID‐19 and immunological regulations-from basic and translational aspects to clinical implications. J Dtsch Dermatol Ges 2020; 18(8): 795-807.
[http://dx.doi.org/10.1111/ddg.14169] [PMID: 32761894]
[24]
Giannetti MP, Weller E, Alvarez-Twose I, et al. COVID-19 infection in patients with mast cell disorders including mastocytosis does not impact mast cell activation symptoms. J Allergy Clin Immunol Pract 2021; 9(5): 2083-6.
[http://dx.doi.org/10.1016/j.jaip.2021.02.023] [PMID: 33631409]
[25]
Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine storm in COVID-19: The current evidence and treatment strategies. Front Immunol 2020; 11: 1708.
[http://dx.doi.org/10.3389/fimmu.2020.01708] [PMID: 32754163]
[26]
Schimuzu M. (2019). Clinical features of cytokine storm syndrome. In: Cronand RQ, Behrens EM, Eds. cytokine storm syndrome. Springer Nature, Switzerland. 31-42.
[http://dx.doi.org/10.1007/978-3-030-22094-5.]
[27]
Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382(18): 1708-20.
[http://dx.doi.org/10.1056/NEJMoa2002032] [PMID: 32109013]
[28]
Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 2020; 130(5): 2620-9.
[http://dx.doi.org/10.1172/JCI137244] [PMID: 32217835]
[29]
Afrin LB, Weinstock LB, Molderings GJ. COVID-19 hyper-inflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome. Int J Infect Dis 2020; 100: 327-32.
[http://dx.doi.org/10.1016/j.ijid.2020.09.016] [PMID: 32920235]
[30]
Abraham SN, St John AL. Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol 2010; 10(6): 440-52.
[http://dx.doi.org/10.1038/nri2782] [PMID: 20498670]
[31]
Theoharides TC, Conti P. COVID-19 and multisystem inflammatory syndrome, or is it mast cell activation syndrome? J Biol Regul Homeost Agents 2020; 34(5): 1633-6.
[PMID: 33023287]
[32]
Valent P, Akin C, Bonadonna P, et al. Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions. J Allergy Clin Immunol 2020; 146(2): 300-6.
[http://dx.doi.org/10.1016/j.jaci.2020.06.009] [PMID: 32561389]
[33]
Afrin LB, Ackerley MB, Bluestein LS, et al. Diagnosis of mast cell activation syndrome: A global “consensus-2”. Diagnosis (Berl) 2021; 8(2): 137-52.
[http://dx.doi.org/10.1515/dx-2020-0005] [PMID: 32324159]
[34]
Ruscitti P, Berardicurti O, Di Benedetto P, et al. Severe COVID-19, another piece in the Puzzle of the hyperferritinemic syndrome. An immunomodulatory perspective to alleviate the storm. Front Immunol 2020; 11: 1130.
[http://dx.doi.org/10.3389/fimmu.2020.01130] [PMID: 32574264]
[35]
Kazama I. Stabilizing mast cells by commonly used drugs: A novel therapeutic target to relieve post-COVID syndrome? Drug Discov Ther 2020; 14(5): 259-61.
[http://dx.doi.org/10.5582/ddt.2020.03095] [PMID: 33116043]
[36]
Weinstock LB, Brook JB, Walters AS, Goris A, Afrin LB, Molderings GJ. Mast cell activation symptoms are prevalent in Long-COVID. Int J Infect Dis 2021; 112: 217-26.
[http://dx.doi.org/10.1016/j.ijid.2021.09.043] [PMID: 34563706]
[37]
Molderings GJ, Haenisch B, Bogdanow M, Fimmers R, Nöthen MM. Familial occurrence of systemic mast cell activation disease. PLoS One 2013; 8(9): e76241.
[http://dx.doi.org/10.1371/journal.pone.0076241] [PMID: 24098785]
[38]
Motta Junior JS, Miggiolaro AFRS, Nagashima S, et al. Mast cells in alveolar septa of COVID-19 patients: A pathogenic pathway that may link interstitial edema to immunothrombosis. Front Immunol 2020; 11: 574862.
[http://dx.doi.org/10.3389/fimmu.2020.574862] [PMID: 33042157]
[39]
Romero-Sánchez CM, Díaz-Maroto I, Fernández-Díaz E, et al. Neurologic manifestations in hospitalized patients with COVID-19. Neurology 2020; 95(8): e1060-70.
[http://dx.doi.org/10.1212/WNL.0000000000009937] [PMID: 32482845]
[40]
Lechowicz K, Drożdżal S, Machaj F, et al. COVID-19: The potential treatment of pulmonary fibrosis associated with SARS-CoV-2 infection. J Clin Med 2020; 9(6): 1917.
[http://dx.doi.org/10.3390/jcm9061917] [PMID: 32575380]
[41]
Ramos L, Peña G, Cai B, Deitch EA, Ulloa L. Mast cell stabilization improves survival by preventing apoptosis in sepsis. J Immunol 2010; 185(1): 709-16.
[http://dx.doi.org/10.4049/jimmunol.1000273] [PMID: 20519642]
[42]
Arsoy HEM, Özdemir Ö. Current therapeutic interventions for COVID-19. Bezmialem Sci 2020; 8(3): 105-16.
[http://dx.doi.org/10.14235/bas.galenos.2020.4758]
[43]
Engin MMN, Özdemir Ö. Potential immunological treatments in COVID-19 patients. Duzce Medical Journal 2021; 23(1): 1-9.
[44]
Kılınc E, Kılınc YB. Mast cell stabilizers as a supportive therapy can contribute to alleviate fatal inflammatory responses and severity of pulmonary complications in COVID-19 infection. Anadolu Kliniği Tıp Bilimleri Dergisi 2020; pp. 111-9.
[45]
Baba A, Tachi M, Ejima Y, et al. Anti-allergic drugs tranilast and ketotifen dose-dependently exert mast cell-stabilizing properties. Cell Physiol Biochem 2016; 38(1): 15-27.
[http://dx.doi.org/10.1159/000438605] [PMID: 26741745]
[46]
Mori T, Abe N, Saito K, et al. Hydrocortisone and dexame-thasone dose-dependently stabilize mast cells derived from rat peritoneum. Pharmacol Rep 2016; 68(6): 1358-65.
[http://dx.doi.org/10.1016/j.pharep.2016.09.005] [PMID: 27710865]
[47]
Malone RW, Tisdall P, Fremont-Smith P, et al. COVID-19: Famotidine, histamine, mast cells, and mechanisms. Front Pharmacol 2021; 12: 633680.
[http://dx.doi.org/10.3389/fphar.2021.633680] [PMID: 33833683]
[48]
Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA 2020; 117(20): 10970-5.
[http://dx.doi.org/10.1073/pnas.2005615117] [PMID: 32350134]
[49]
Lombardy Section Italian Society Infectious And Tropical Diseases. Vademecum for the treatment of people with COVID-19 (Edition 2.0, 13 March 2020. Infez Med.). 2020; 28(2): 143-52.
[50]
Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents 2020; 55(5): 105954.
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105954] [PMID: 32234467]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy